Skip to main content

Table 3 Adverse events

From: IMRT and carbon ion boost for malignant salivary gland tumors: interim analysis of the COSMIC trial

   R2: visible residual tumor   R1: R1/ Pn + resected tumors  
   end of RT 1st f/u end of RT 1st f/u
Mucositis I 3 (18.8%) 1 (6.3%) 4 (30.8%) 0
  II 7 (43.8%) 0 6 (46.2%) 0
  III 4 (25%) 0 2 (15.4%) 0
Dermatitis I 13 (81.3%) 0 12 (92.3%) 1 (7.7%)
  II 2 (12.5%) 0 0 0
  III 1 (6.3%) 0 1 (7.7%) 0
Xerostomia I 7 (43.8%) 10 (62.5%) 6 (46.2%) 11 (84.6%)
  II 0 2 (12.5%) 2 (15.4%) 0
Dysphagia I 7 (43.8%) 2 (12.5%) 4 (30.8%) 0
  II 0 0 2 (15.4%) 0
  III 0 0 0 0
Weight loss yes 13 (81.3%) 3 (18.8%) 9 (69.2%) 4 (30.8%)
kg median 5   5,5  
  min 3   5  
  max 10   12  
Feeding tube 0 0 0 0
Loss of taste   16 (100%) 0 11 (84.6%) 0
Middle ear effusion 6 (37.5%) 5 (31.3%) 2 (15.4%) 2 (15.4%)
Otitis   0 0 0 0
Paralysis of facial nerve 1 (6.3%) 1 (6.3%) 1 (7.7%) 1 (7.7%)
Ptosis   1 (6.3%) 1 (6.3%) 0 0
Reduced jaw opening 2 (12.5%) 2 (12.5%) 1 (7.7%) 1 (7.7%)
Xerophthalmia 0 1 (6.3%) 1 (7.7%) 0
Conjunctivitis 1 (6.3%) 0 0 0
Lymph edema 1 (6.3%) 1 (6.3%) 0 2 (15.4%)
Hearing impairment 2 (12.5%) 0 0 0